Nestle Health Science
Privately held: no public share price
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Approved | —Microbiome therapeutic | Clostridioides Difficile Infection Recurrent Clostridioides Difficile Infection |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $8.0B | — | — | — | report ↗ |